New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...

DexCom, Inc. DXCM recently collaborated with Companion Medical to enable a direct exchange of CGM (Continuous Glucose Monitoring) data from InPen into both the companies’ software applications. The ...

DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results , with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, ...

DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this ...

Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong ...

Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness ...